معرفی
Miguel N. Rivera, MD is an Associate Professor of Pathology at Harvard Medical School and Assistant Molecular Pathologist at Massachusetts General Hospital (MGH). He serves as Associate Member of the Broad Institute and holds the Thomas F. and Diana L. Ryan MGH Research Scholar title. His laboratory operates within MGH's Molecular Pathology Unit and Krantz Family Center for Cancer Research.
Dr. Rivera's educational background includes:
- MD from Harvard Medical School
- Residency at Brigham and Women's Hospital
His research centers on cancer genomics and pediatric oncology, utilizing genomic technologies to dissect gene regulation pathways in tumors. The Rivera Lab specializes in epigenomic profiling of pediatric cancers including Wilms tumor, Ewing sarcoma, and medulloblastoma, with emphasis on chromatin remodeling, transcriptional dysregulation, and tumor suppressor mechanisms like the WTX gene family. This work bridges fundamental molecular discoveries with therapeutic development for childhood cancers.
Analysis of Dr. Rivera's publication record reveals consistent innovation in genomic methodologies applied to pediatric solid tumors. His research trajectory shows progression from foundational tumor suppressor gene discovery (WTX in Wilms tumor) to cutting-edge investigations of chromatin architecture, disordered proteins, and 3D genome organization in sarcomas. The work demonstrates strong translational potential, particularly in targeting intrinsically disordered domains as evidenced by the 2024 Krantz Breakthrough Award.
Dr. Rivera's scientific recognition includes:
- Thomas F. and Diana L. Ryan MGH Research Scholar
- Krantz Family Center for Cancer Research Breakthrough Award (2024) for "Targeting intrinsically disordered protein domains in cancer"
The Rivera Lab receives substantial research support within MGH's $19 million pathology research infrastructure. His current projects include epigenomic mapping of pediatric cancer pathways and functional characterization of the WTX gene family using biochemical and genomic tools. The lab maintains active collaborations across Harvard Medical School, Broad Institute, and Krantz Center networks.
Based in MGH's 20,000 sq. ft. pathology research facility, the Rivera Lab team comprises postdoctoral researchers and scientists investigating transcriptional dysregulation in pediatric cancers. Current initiatives focus on prion-like domains in Ewing sarcoma (2024 Krantz project) and WTX-related mechanisms in development and cancer using in vitro and in vivo models.
